Antibacterial and antivirulence activities of abafungin against Clostridioides difficile : in vitro and in vivo studies
Antimicrobial Agents and Chemotherapy · 2026
DOI: 10.1128/aac.00598-26 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2026. Verfasst von Ahmed A Abouelkhair und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Sciences and Pathobiology, Virginia-Maryland College of Veterinary Medicine, Virginia Polytechnic Institute and State Univer…. Hauptthemen laut MEDLINE: Clostridioides difficile, Vancomycin, Spores, Bacterial, Clostridium Infections. Die Arbeit nennt 82 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Clostridioides difficile infection (CDI) remains a major cause of healthcare-associated diarrhea worldwide, and is classified as an urgent public health threat by the Centers for Disease Control and Prevention. Current frontline therapies, including vancomycin and fidaxomicin, are associated with disruption of the intestinal microbiota, recurrence, and emerging reduced susceptibility, underscoring the need for additional therapeutic strategies. Using a drug-repurposing approach, we identified the antifungal agent abafungin as a potent inhibitor of C. difficile . Abafungin is an arylguanidine antifungal with reported sporicidal activity against fungal pathogens, a property of particular relevance to CDI, given the central role of spores in disease persistence and recurrence. Herein, abafungin exhibited potent in vitro activity against a diverse panel of clinical C. difficile isolates, inhibiting 50% (MIC 5₀ ) and 90% (MIC ₉₀ ) of the tested strains at the concentrations of 0.25 μg/mL and 0.5 μg/mL, respectively, while demonstrating minimal activity against representative gut commensal bacteria. At sub-inhibitory concentrations, abafungin significantly reduced toxin production (31.8%), decreased spore formation (~4-log₁₀ reduction), and inhibited spore germination. Abafungin showed favorable gastrointestinal stability and demonstrated synergistic activity with vancomycin and metronidazole. Transcriptomic analysis revealed that abafungin disrupts metal ion transport and intracellular metal homeostasis in C. difficile , a mechanism supported by the antagonistic effect of Mg² + supplementation on its antibacterial activity. These observations suggest a potential association between abafungin activity and metal-responsive cellular pathways. In a murine model of recurrent CDI, a combination therapy of abafungin and vancomycin significantly improved survival (83.3%) compared with vancomycin monotherapy (16.6%). Collectively, these findings establish abafungin as a potential anti -C . difficile inhibitor that suppresses C. difficile growth and virulence-associated processes and enhances the therapeutic efficacy of vancomycin in vivo . Also, these observations provide a basis for further studies exploring abafungin as a useful lead scaffold for anti -C . difficile drug discovery.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biomedical Sciences and Pathobiology, Virginia-Maryland College of Veterinary Medicine, Virginia Polytechnic Institute and State University, Blacksburg, Virginia, USA.
- Department of Bacteriology, Mycology, and Immunology, Faculty of Veterinary Medicine, University of Sadat City, Sadat City, Menofia, Egypt.
- Department of Microbiology and Immunology, Faculty of Pharmacy, Zagazig University, Zagazig, Al-Sharqia, Egypt.
- Department of Plant Pathology, Faculty of Agriculture, Assiut University, Assiut, Egypt.
- Center for One Health Research, Virginia Polytechnic Institute and State University, Blacksburg, Virginia, USA.
ORCID-Profile: Ahmed A Abouelkhair, Nader S Abutaleb, Mohamed N Seleem
Förderung
- NIAID NIH HHS
- NIH HHS
- National Institutes of Health
Zitieren
APA
Abouelkhair, A. A., Abutaleb, N. S., Abdelrazek, S., & Seleem, M. N. (2026). Antibacterial and antivirulence activities of abafungin against Clostridioides difficile : in vitro and in vivo studies. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00598-26
Vancouver
Abouelkhair AA, Abutaleb NS, Abdelrazek S, Seleem MN. Antibacterial and antivirulence activities of abafungin against Clostridioides difficile : in vitro and in vivo studies. Antimicrobial Agents and Chemotherapy. 2026. doi:10.1128/aac.00598-26
BibTeX
@article{Abouelkhair2026,
author = {Abouelkhair, Ahmed A and Abutaleb, Nader S and Abdelrazek, Sahar and Seleem, Mohamed N},
title = {Antibacterial and antivirulence activities of abafungin against Clostridioides difficile : in vitro and in vivo studies},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2026},
doi = {10.1128/aac.00598-26}
}
EUVIMED